Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
AveXis, Inc. (AVXS) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/15/2018 8-K Resignation/termination of a director
Docs: "AMENDED AND RESTATED CERTIFICATE OF INCORPORATION",
"AMENDED AND RESTATED BY-LAWS"
05/03/2018 8-K Quarterly results
Docs: "AveXis Reports First Quarter 2018 Financial and Operating Results"
04/25/2018 8-K Quarterly results
04/24/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "AveXis Presents Initial Data from Pivotal U.S. Trial for SMA Type 1 and 24-Month Follow-Up Data from Phase 1 Trial of AVXS-101 in SMA Type 1 at the Annual Meeting of the American Academy of Neurology"
04/09/2018 8-K Acquisition/merger/asset purchase announced
Docs: "Agreement and Plan of Merger, among Novartis AG, Novartis AM Merger Corporation, and AveXis, Inc",
"Amendment to the Amended and Restated Bylaws of AveXis, Inc",
"Press Release of AveXis, Inc."
03/27/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "AveXis Gene Therapy Awarded SAKIGAKE Designation for Spinal Muscular Atrophy Type 1 Chicago, Ill. — AveXis, Inc. , a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today announced that Japan's Ministry of Health, Labour and Welfare awarded the company's initial product candidate, AVXS-101, SAKIGAKE Designation for the treatment of spinal muscular atrophy Type 1. The designation was based on data from the Phase 1 clinical trial of the company's proprietary gene therapy. SAKIGAKE is intended to promote research and development in Japan for innovative new medical products that satisfy certain criteria, such as the severity of the intended indication, by providing prioritized consultation review dur..."
03/13/2018 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "AveXis Enters into Licensing Agreement with Genethon"
02/27/2018 8-K Quarterly results
Docs: "AveXis Reports Fourth Quarter and Full Year 2017 Financial and Operating Results",
"Slide Presentation dated February 27, 2018, titled “Rett Syndrome and Genetic ALS with SOD1 Mutation.”"
01/30/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "AveXis to Initiate Screening for Remaining Patients in Pivotal Trial of AVXS-101 for SMA Type 1 Following Review of Preliminary Data from First Three Patients Chicago, Ill. — AveXis, Inc. , a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today announced that, following review of safety data and early signals of efficacy from the first three patients dosed in its pivotal trial of AVXS-101 for spinal muscular atrophy Type 1, the company, with agreement from the U.S. Food and Drug Administration, will initiate screening for the remaining patients in the trial as per the protocol. The open-label, single-arm, multi-center trial is designed to evaluate the efficacy and safety of a one-time intravenou..."
01/18/2018 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Underwriting Agreement",
"Opinion of Cooley LLP",
"AveXis Announces Pricing of Public Offering of Common Stock"
01/16/2018 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Docs: "AveXis Announces Proposed Public Offering of Common Stock",
"AveXis Announces Expanded Clinical Development Program for AVXS-101 in Spinal Muscular Atrophy"
01/09/2018 8-K Quarterly results
01/04/2018 8-K Quarterly results
12/13/2017 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Docs: "Slide Presentation, titled “Phase 1 SMA Type 2 Trial Initiation and Study Design.”",
"AveXis Announces Plan to Initiate Phase 1 Trial in SMA Type 2 Utilizing Intrathecal Delivery of AVXS-101"
11/09/2017 8-K Quarterly results
Docs: "AveXis Reports Third Quarter 2017 Financial and Operating Results"
10/19/2017 8-K Quarterly results
10/03/2017 8-K Other Events, Financial Statements and Exhibits
Docs: "AveXis to Report Top-line Data from the Phase 1 Clinical Trial of AVXS-101 in SMA Type 1 at the International Annual Congress of the World Muscle Society"
09/29/2017 8-K Quarterly results
08/10/2017 8-K Quarterly results
Docs: "AveXis Reports Second Quarter 2017 Financial and Operating Results"
07/14/2017 8-K Form 8-K - Current report:
06/22/2017 8-K Form 8-K - Current report
06/19/2017 8-K Form 8-K - Current report
06/14/2017 8-K Form 8-K - Current report
06/07/2017 8-K Form 8-K - Current report
06/02/2017 8-K Form 8-K - Current report
05/11/2017 8-K Form 8-K - Current report
04/25/2017 8-K Form 8-K - Current report
04/19/2017 8-K Form 8-K - Current report
03/16/2017 8-K Form 8-K - Current report
02/06/2017 8-K Form 8-K - Current report
01/09/2017 8-K Form 8-K - Current report
12/21/2016 8-K Form 8-K - Current report
11/10/2016 8-K Form 8-K - Current report
11/01/2016 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy